India’s Opposition Party Candidate Critical Of Ranbaxy Buyout
This article was originally published in PharmAsia News
The proposed acquisition of India's Ranbaxy Laboratories by Japan's Daiichi Sankyo has drawn the ire of the leader of India's opposing party, who called it "a cause for worry." Opposition leader L.K. Advani of the Bharatiya Janata Party said, without naming Ranbaxy, it "has lost its identity to a foreign company" by acceding to the buyout bid. Advani acknowledged mergers and acquisitions involving Indian companies were inevitable, but said the companies should consider national interests, which he said are antithetical to monopolies in areas such as pharmaceuticals. (Click here for more
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.